Polymeric micelles for breast cancer therapy: recent updates, clinical translation and regulatory considerations

Vijayabhaskarreddy Junnuthula*, Praveen Kolimi, Dinesh Nyavanandi, Sunitha Sampathi, Lalitkumar K. Vora, Sathish Dyawanapelly

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

57 Citations (Scopus)
121 Downloads (Pure)

Abstract

With the growing burden of cancer, parallel advancements in anticancer nanotechnological solutions have been witnessed. Among the different types of cancers, breast cancer accounts for approximately 25% and leads to 15% of deaths. Nanomedicine and its allied fields of material science have revolutionized the science of medicine in the 21st century. Novel treatments have paved the way for improved drug delivery systems that have better efficacy and reduced adverse effects. A variety of nanoformulations using lipids, polymers, inorganic, and peptide-based nanomedicines with various functionalities are being synthesized. Thus, elaborate knowledge of these intelligent nanomedicines for highly promising drug delivery systems is of prime importance. Polymeric micelles (PMs) are generally easy to prepare with good solubilization properties; hence, they appear to be an attractive alternative over the other nanosystems. Although an overall perspective of PM systems has been presented in recent reviews, a brief discussion has been provided on PMs for breast cancer. This review provides a discussion of the state-of-the-art PMs together with the most recent advances in this field. Furthermore, special emphasis is placed on regulatory guidelines, clinical translation potential, and future aspects of the use of PMs in breast cancer treatment. The recent developments in micelle formulations look promising, with regulatory guidelines that are now more clearly defined; hence, we anticipate early clinical translation in the near future.

Original languageEnglish
Article number1860
JournalPharmaceutics
Volume14
Issue number9
DOIs
Publication statusPublished - 03 Sept 2022

Bibliographical note

Funding Information:
S.D. is thankful to the Institute of Chemical Technology, Mumbai, India. V.J. is supported by a personal research grant from the Finnish Cultural Foundation (Ingrid, Toini and Olavi Martelius foundation). S.S., thankful to GITAM School of Pharmacy, GITAM Deemed to be University. and were created with biorender.com (accessed on 19 July 2022).

Publisher Copyright:
© 2022 by the authors.

Keywords

  • bioavailability
  • breast cancer
  • clinical translation
  • drug delivery
  • polymeric micelles
  • regulatory affairs

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Polymeric micelles for breast cancer therapy: recent updates, clinical translation and regulatory considerations'. Together they form a unique fingerprint.

Cite this